This is just a parent page for easy ordering
This is just a parent page for easy ordering
Zebra’s bone density algorithm uses existing CT scans, performed for any reason, to output a result which is equivalent to the Bone Density T-Score generated by DEXA scans.
Providers can use their existing CT data to conduct prescreening for people with increased risk of fracture, with no need for additional tests or radiation. These can then be targeted for Bone Health or Fracture Prevention programs, reducing overall fracture rates and associated costs.
Osteoporosis affects 1/3 women and 1/5 men over 50 and is responsible for 9M fractures globally every year. 80% of those at risk are not identified or treated, and patients who suffer from an Osteoporotic fracture experience significant degradation in their quality of life – 25% of hip fracture patients end up in a nursing home within 12 months of their fracture. The costs of Osteoporosis treatment are estimated to be $17 Billion in the US alone.
One of the parameters used to identify patients at risk of Osteoporosis is bone density. A DEXA scan provides a T-Score, which along with other risk factors gives an indication of the likelihood of Osteoporosis. Unfortunately, few people actively seek to monitor their bone density, and DEXA scans are only performed by a small percentage of the population. This perpetuates the low identification rate.
Zebra’s fatty liver algorithm analyses CT Chest / Abdomen data to automatically segment the liver, and calculates its average density. When detected in time, fatty liver can be reversible with lifestyle modifications involving diet, exercise and reduced alcohol intake. This algorithm can provide a ‘wake up’ call to pre-diabetics to spur lifestyle interventions.
Fatty Liver is common, found incidentally on CT in 11.4% of the adult population in the US and in 22% among diabetics. Fatty liver is a risk factor for several key preventable diseases. Presence of fatty liver is associated with subclinical cardiovascular changes, elevated inflammatory markers of atherosclerosis and heart dysfunction. In diabetics (type II), fatty liver is associated with coronary artery disease.
It is also independently associated with increased coronary artery calcification and is a strong predictor of high-risk coronary artery plaque. The presence of fatty liver indicates 2.13x – 4.6x risk of having high risk coronary artery plaque. People with fatty liver are nearly 2x as likely to experience a cardiovascular event (heart attack or sudden death) over a mean follow up interval of 7.3 years.
Zebra’s Coronary Calcium Scoring algorithm automatically calculates Coronary Calcium Scores based on standard, non-contrast Chest CTs. This tool can provide early detection of people at high risk of severe cardiovascular events.
Coronary artery calcium is a biomarker of coronary artery disease – and quantification of coronary calcification is a strong predictor for cardiovascular events such as heart attack or strokes.
Conventional coronary calcium scoring has required dedicated cardiac, ECG gated CT performed with and without contrast. Recently, the reliable derivation of coronary calcium score has been obtained algorithmically from low dose chest CT data (Isgum et al. 2012); the automatically derived score was predictive of cardiovascular events in a large cohort of individuals undergoing CT lung cancer screening.
Zebra’s emphysema algorithm analyzes CT Chest studies, detects emphysematous regions in the lungs, and quantifies the volume of emphysema in comparison to the overall lung volume.
A more accurate understanding of the prevalence of the disease within a given population can help patients manage the disease more effectively before it degrades to more severe, less treatable manifestations.
Emphysema is one of the diseases that comprises COPD (chronic obstructive pulmonary disease). It is a long-term, progressive obstructive lung disease in which the alveoli (small sacs) that promote oxygen-carbon dioxide exchange between the air and the bloodstream become damaged or destroyed. There are approximately 12 million individuals in the US who carry a diagnosis of COPD and the American Lung Association estimates that there were twice as many patients with impaired lung function (indicative of early stage COPD) than patients with diagnosed COPD. COPD is the third leading cause of death behind heart disease and cancer, and current estimates suggest that COPD costs the nation almost $50 billion annually in both direct and indirect health expenditures.